Prevalence of Delayed Chemotherapy Associated Nausea

Delayed Chemotherapy-induced Nausea: A Multi-center Prevalence Survey in Adult Oncology Patients in Clinical Practice

This study evaluates the prevalence of delayed chemotherapy induced nausea in adult oncology patients in real clinical practice of day clinics.

Chemotherapies are rated to have a high to minimal emetogenic potential in oncology patients. Their potential to induce delayed nausea is supposed to often be higher than their emetogenic potential. However, data on delayed chemotherapy-related nausea are scarce, which is problematic because nausea (a) has a large impact on patients quality of life and treatment decisions, (b) is often underestimated by health care professionals, (c) is less responsive to commonly used antiemetic medication, and (d) may even be different from rates that have been established in controlled clinical trials.

Therefore, the aim of this study is to assess the prevalence of delayed chemotherappy-induced nausea in adult oncology patients in dayclinics.

Inclusion Criteria:

• first day of chemotherapy of a new cycle (any cycle)
• speak and write German
• sign the consent forms

Exclusion Criteria:

• cognitive or linguistic impairments that would significantly impede consent or participation (as assessed by the nurses in charge)
• accompanying radiotherapy;
• pre-existing nausea within three days before the start of the first chemotherapy in this cycle; and
• prior participation in CINrate (each person participates only once)